1. Home
  2. FABC vs ALLR Comparison

FABC vs ALLR Comparison

Compare FABC & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fabric.AI Inc. Common Stock

FABC

Fabric.AI Inc. Common Stock

N/A

Current Price

$2.43

Market Cap

19.9M

ML Signal

N/A

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

21.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FABC
ALLR
Founded
N/A
2004
Country
United States
United States
Employees
108
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.9M
21.5M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
FABC
ALLR
Price
$2.43
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.75
AVG Volume (30 Days)
164.8K
75.7K
Earning Date
N/A
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,579,745.00
$320,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.31
$0.77
52 Week High
$4.57
$1.88

Technical Indicators

Market Signals
Indicator
FABC
ALLR
Relative Strength Index (RSI) 39.22 39.68
Support Level N/A $1.22
Resistance Level $2.98 $1.45
Average True Range (ATR) 0.17 0.09
MACD -0.03 -0.02
Stochastic Oscillator 11.82 14.61

Price Performance

Historical Comparison
FABC
ALLR

About FABC Fabric.AI Inc. Common Stock

Fabric.AI Inc is an infrastructure company building a suite of fabless semiconductor technologies to power AI factories - smart data centers optimized for producing intelligence at scale. The company's innovations include MicroLED-based optical interconnects and other system-critical technologies that enable faster, more efficient, and more scalable AI workloads. Its mission is to transform data centers into unified production systems for artificial intelligence.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Share on Social Networks: